Cancel anytime
GE HealthCare Technologies Inc. (GEHC)
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- PASS (Skip invest)*
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
12/11/2024: GEHC (3-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type: Stock | Upturn Star Rating | Today’s Advisory: PASS |
Historic Profit: 13.64% | Upturn Advisory Performance 3 | Avg. Invested days: 48 |
Profits based on simulation | Stock Returns Performance 2 | Last Close 12/11/2024 |
Type: Stock | Today’s Advisory: PASS |
Historic Profit: 13.64% | Avg. Invested days: 48 |
Upturn Star Rating | Stock Returns Performance 2 |
Profits based on simulation Last Close 12/11/2024 | Upturn Advisory Performance 3 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 37.81B USD |
Price to earnings Ratio 22.67 | 1Y Target Price 96.81 |
Dividends yield (FY) 0.17% | Basic EPS (TTM) 3.65 |
Volume (30-day avg) 3441837 | Beta - |
52 Weeks Range 71.23 - 94.52 | Updated Date 12/12/2024 |
Company Size Large-Cap Stock | Market Capitalization 37.81B USD | Price to earnings Ratio 22.67 | 1Y Target Price 96.81 |
Dividends yield (FY) 0.17% | Basic EPS (TTM) 3.65 | Volume (30-day avg) 3441837 | Beta - |
52 Weeks Range 71.23 - 94.52 | Updated Date 12/12/2024 |
Earnings Date
Report Date - | When - |
Estimate - | Actual - |
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 8.56% | Operating Margin (TTM) 16.06% |
Management Effectiveness
Return on Assets (TTM) 5.64% | Return on Equity (TTM) 21.85% |
Revenue by Products
Revenue by Geography
Valuation
Trailing PE 22.67 | Forward PE 17.86 |
Enterprise Value 44989239012 | Price to Sales(TTM) 1.93 |
Enterprise Value to Revenue 2.3 | Enterprise Value to EBITDA 12.98 |
Shares Outstanding 456872992 | Shares Floating 442522599 |
Percent Insiders 3.09 | Percent Institutions 83.53 |
Trailing PE 22.67 | Forward PE 17.86 | Enterprise Value 44989239012 | Price to Sales(TTM) 1.93 |
Enterprise Value to Revenue 2.3 | Enterprise Value to EBITDA 12.98 | Shares Outstanding 456872992 | Shares Floating 442522599 |
Percent Insiders 3.09 | Percent Institutions 83.53 |
Analyst Ratings
Rating 4.05 | Target Price 88 | Buy 3 |
Strong Buy 10 | Hold 6 | Sell - |
Strong Sell 1 |
Rating 4.05 | Target Price 88 | Buy 3 | Strong Buy 10 |
Hold 6 | Sell - | Strong Sell 1 |
AI Summarization
GE HealthCare Technologies Inc. - A Comprehensive Overview
Company Profile:
History and Background:
GE HealthCare Technologies Inc. (GEHC) is a global medical technology and digital solutions company, spun off from General Electric in January 2023. The company's legacy goes back to the founding of General Electric in 1892, with a long history of innovation in healthcare technologies. GEHC focuses on providing medical imaging, ultrasound, patient monitoring, and diagnostics solutions.
Core Business Areas:
- Medical Imaging: X-ray, CT, MRI, Nuclear Medicine, and Ultrasound systems.
- Patient Monitoring and Life Support: Anesthesia, respiratory care, and hemodynamic monitoring solutions.
- Diagnostics: Laboratory and molecular diagnostics.
- Digital Solutions: Software and analytics for medical imaging, patient care, and operational efficiency.
Leadership and Corporate Structure:
- CEO: Kieran Murphy
- CFO: B. Joseph de Perio
- Chief Technology Officer: Simon Judkins
- Head of Human Resources: Cindy Borin
- Board of Directors: Led by Helen G. Drinan
Top Products and Market Share:
Top Products:
- CT Scanners (Revolution series)
- MRI scanners (Signa series)
- Ultrasound systems (Voluson series)
- Patient monitors (Bently series)
- Laboratory diagnostics (CENTAUR series)
Market Share:
- Global Medical Imaging: ~14%
- US Medical Imaging: ~17%
- Global Patient Monitoring: ~22%
- US Patient Monitoring: ~28%
Product Performance and Market Reception:
GEHC's products are recognized for their advanced technology, clinical performance, and user-friendly design. They receive positive feedback from healthcare professionals and consistently rank among the top in industry comparisons.
Total Addressable Market:
The global medical technology market is estimated to be worth over $500 billion in 2023, with a projected CAGR of 5.5%. The US market represents approximately 40% of the global market.
Financial Performance:
Recent Financials:
- Revenue (2022): $18.2 billion
- Net Income (2022): $1.3 billion
- Profit Margin (2022): 7.1%
- EPS (2022): $1.04
Year-over-Year Performance:
- Revenue grew by 2% in 2022 compared to 2021.
- Net Income declined by 10% in 2022 compared to 2021.
- EPS decreased by 11% in 2022 compared to 2021.
Cash Flow and Balance Sheet:
GEHC has a strong cash flow position and a healthy balance sheet. The company has a low debt-to-equity ratio and ample liquidity.
Dividends and Shareholder Returns:
Dividend History:
GEHC has a history of paying dividends, with a current annual dividend yield of approximately 0.5%.
Shareholder Returns:
Over the past year, GEHC's stock price has declined by approximately 15%. Over the past five years, shareholder returns have been positive, with a total return of approximately 20%.
Growth Trajectory:
Historical Growth:
GEHC's revenue has grown at a CAGR of approximately 3% over the past five years.
Future Growth Projections:
Analysts project GEHC's revenue to grow at a CAGR of approximately 4% over the next five years.
Growth Prospects:
GEHC's growth prospects are supported by several factors, including:
- Increasing demand for medical technology driven by an aging population.
- Growing adoption of digital healthcare solutions.
- Expanding presence in emerging markets.
Market Dynamics:
Industry Trends:
The medical technology industry is characterized by:
- Technological innovation
- Consolidation
- Value-based healthcare
- Artificial intelligence and machine learning
GEHC's Positioning:
GEHC is well-positioned within the industry due to its strong brand recognition, innovative products, and global reach. The company is also actively investing in digital solutions and artificial intelligence to stay ahead of the curve.
Competitors:
Key Competitors:
- Medtronic (MDT)
- Siemens Healthineers (SHL)
- Philips (PHG)
- Abbott Laboratories (ABT)
Market Share:
GEHC's main competitors have similar market shares in the medical technology industry, with Medtronic and Siemens Healthineers having slightly larger shares.
Competitive Advantages:
GEHC's competitive advantages include:
- Strong brand reputation
- Broad product portfolio
- Global reach
- Focus on innovation
Competitive Disadvantages:
GEHC's competitive disadvantages include:
- High capital expenditures
- Dependence on cyclical healthcare spending
Potential Challenges and Opportunities:
Key Challenges:
- Supply chain disruptions
- Technological advancements
- Competitive pressures
- Regulatory changes
Potential Opportunities:
- Expanding into new markets
- Developing new product innovations
- Forming strategic partnerships
Recent Acquisitions:
In the past three years, GEHC has made several acquisitions to expand its product portfolio and enter new markets. Notable acquisitions include:
- BK Medical (2021): Ultrasound imaging systems for urology and surgery.
- Caption Health (2021): AI-powered software for stroke detection.
- Prismatic Sensors (2022): Sensors for patient monitoring.
These acquisitions align with GEHC's strategy to focus on innovative and clinically-differentiated solutions in medical imaging, patient monitoring, and digital healthcare.
AI-Based Fundamental Rating:
Rating:
Based on an AI-based analysis of GEHC's fundamentals, the company receives a rating of 7.5 out of 10.
Justification:
This rating is supported by GEHC's strong financial performance, leading market positions in several key product categories, and potential for future growth. However, the company faces challenges from intense competition and the need to adapt to rapidly evolving technologies.
Sources and Disclaimers:
Sources:
- GE HealthCare Technologies Inc. investor relations website
- SEC filings
- Industry reports
- News articles
Disclaimer:
This information is provided for educational purposes only and should not be considered investment advice. Investors should conduct their research and consult with a financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About GE HealthCare Technologies Inc.
Exchange | NASDAQ | Headquaters | Chicago, IL, United States |
IPO Launch date | 2023-01-04 | President, CEO & Director | Mr. Peter J. Arduini |
Sector | Healthcare | Website | https://www.gehealthcare.com |
Industry | Health Information Services | Full time employees | 51000 |
Headquaters | Chicago, IL, United States | ||
President, CEO & Director | Mr. Peter J. Arduini | ||
Website | https://www.gehealthcare.com | ||
Website | https://www.gehealthcare.com | ||
Full time employees | 51000 |
GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, image-guided therapy, X-ray systems, and women's health products. The Ultrasound segment provides medical devices and solutions for screening, diagnosis, treatment, and monitoring of certain diseases in clinical areas, such as radiology and primary care, women's health, cardiovascular, and point of care and handheld ultrasound solutions, as well as surgical visualization and guidance products. The Patient Care Solutions segment provides medical devices, consumables, services, and digital solutions. Its portfolio includes patient monitoring solutions, anesthesia delivery and respiratory care products, electrocardiogram solutions, maternal infant care products, and consumables and services. The Pharmaceutical Diagnostics supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, positron emission tomography, and ultrasound to the radiology and nuclear medicine industry. The segment also provides contrast media pharmaceuticals that are administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes. It has an AI collaboration with Mass General Brigham. The company was formerly known as GE Healthcare Holding LLC and changed its name to GE HealthCare Technologies Inc. in December 2022. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.